



ANNEX A

DIFFERENCES BETWEEN STDR PRE-PILOT (STREAM 1&2) AND PILOT STAGES

The **Pre-Pilot** stage aims to support earlier-stage and more exploratory, proof-of-concept projects with some preliminary data. Areas supported include the preclinical validation of drug targets, or platform exploration.

The **Pilot** stage aims to support more mature projects that have more data and have already been validated to a certain degree, or already have a commercialisation plan.

Comparisons between Pre-Pilot and Pilot

<u>Pre-Pilot Stream 1 (Target Validation)</u>	<u>Pre-Pilot Stream 2 (Platform Development)</u>
<p>Stage: Preliminary data supporting the implication of a target in a given disease indication, with new data generated by the applicant and/or key published experiments reproduced by the applicant.</p> <p>The target should have a novel role in the indication chosen by the applicant.</p> <p>Note: Large scale compound screening, Hit-to-Lead or Lead-optimisation cannot be supported by the Pre-Pilot Stream 1.</p> <p>Examples of projects:</p> <ul style="list-style-type: none">• Validation of XXX as a relevant target against xyz indications• Peptides as tool inhibitors of XXX for xyz indications• Novel Biomarker and therapeutic target in xyz indications• Validating the tractability of XXX as a target for antibody therapeutics <p>Mentorship/training: A Drug Discovery Specialist (DDS) will be appointed to each project to work with the investigator on the design of key experiments needed for preclinical target validation.</p> <p>Intended outcome: Target validation, more convincing evidence of whether the target should be considered for a drug discovery campaign, a streamlined shorter process to advance to the Pilot for selected high potential projects.</p>	<p>Stage: Preliminary data supporting the proof of concept for a platform technology.</p> <p>An indication of the scope of applications but no specific set of key commercial applications defined.</p> <p>Definition of platforms: Platforms are technologies that enable broad application of the underlying science and in so doing, create value by enabling multiple applications or products.</p> <p>Examples of projects:</p> <ul style="list-style-type: none">• The invention of CRISPR technology for genome editing as enabling broader applications of genetic engineering to meet unmet medical needs• Generalisable combinatorial screening platform for unbiased interaction discovery• Microfluidics for High-throughput Antibody discovery against XXX• XXX cell-derived cancer immunotherapy platform <p>Mentorship/training: Projects will be supported with a venture exploration bootcamp organised by SMART that will help to scope out the key potential applications with commercial impact and help outline the commercialisation pathway.</p> <p>Intended outcome: Validation of the platform and a clearer commercialisation pathway, a streamlined shorter process to advance to the Pilot for selected high potential projects.</p>



Pilot

Stage: Funds more mature projects that have already been validated to a certain degree. Both single target/single asset projects and platform technologies projects will be funded, in a range of stages from target validation to preclinical work.

For single-asset projects: Data demonstrating that

- i. The target is implicated in the disease indication;
- ii. The target can be modulated therapeutically;
- iii. Modulation of the target may lead to a therapeutic effect in relevant pre-clinical models; and/or
- iv. A defined path towards the development of a therapeutic candidate.

Example workplan for single-asset Pilot projects:

- Phase 1 – Identification of target modulators (e.g. high-throughput screening), lead generation, preliminary evaluation of efficacy and safety of candidates in-vitro and in-vivo, development of in-vivo models for preclinical assessment.
- Phase 2 – Optimisation of lead candidates, development planning, initial preclinical development.

For platform technologies:

Data supporting and establishing the platform technology, such as early data showing two or more applications, and a clear pathway articulated to select and demonstrate a first commercial product.

Example workplan for platform technologies Pilot projects:

- Phase 1 – Platform development and venture design including identification of business model and lead indication and/or sub-indications.
- Phase 2 – Further platform development and venture execution.

Mentorship/training: Pilot awardees will attend mentoring sessions to receive advice and support from leading entrepreneurs and innovators (including VCs, biotech CEOs, or experts from EDDC). Mentors will provide advice on matters relating to the development and commercial strategy, including marketing, business modelling and pitch practice/advice.

Selected awardees will attend a bootcamp organised by SMART that will help clarify the key commercial applications and define a development pathway for the pilot application.

Intended outcome: Allow projects to have sufficient funding to bridge the gap to the next value inflexion point in the drug discovery and development pathway. Outcomes include follow-on funding from private funders, co-development with industry or entry into EDDC's portfolio.